AI Article Synopsis
- This review addresses the need for better understanding and management of drug-induced liver injury (DILI) associated with monoclonal antibody therapies (MTA) to improve cancer treatment outcomes.
- A comprehensive literature review was conducted, utilizing resources like case reports, FDA documents, and the LiverTox database to gather information on MTA-related hepatotoxicity.
- Although MTA-related liver issues are common, they are rarely life-threatening, and potential predictive methods like pharmacogenomics exist, but more research is needed; preventive measures focus on managing viral hepatitis and avoiding risky drug combinations.
Article Abstract
Introduction: Understanding the mechanism of DILI with MTA, and how to avoid and manage these toxicities is essential for minimising inferior cancer treatment outcomes. An organised and comprehensive overview of MTA-associated hepatotoxicity is lacking; this review aims to fill the gap.
Areas Covered: A literature review was performed based on published case reports and relevant studies or articles pertaining to the topics on PubMed. Food and Drug Administration drug information documents and search on the US National Library of Medicine LiverTox database was performed for all relevant MTA.
Expert Opinion: MTA-associated hepatotoxicity is common but rarely fatal. The pattern of hepatotoxicity is predominantly idiosyncratic. Pharmacogenomics show potential in predicting patients at risk of poorly metabolising or developing immunoallergic responses to MTA, but prospective data is scant. Preventing reactivation of viral hepatitis using anti-viral drugs, and avoidance of drug combinations at high risk of negative interactions are the most readily preventable measures for DILI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425255.2016.1190831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatotoxicity of targeted therapy for cancer.
Expert Opin Drug Metab Toxicol
July 2016
a Sir YK Pao Center for Cancer, Department of Clinical Oncology, State Key Laboratory in Oncology in South China , The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, Shatin , Hong Kong.
Article Synopsis
- This review addresses the need for better understanding and management of drug-induced liver injury (DILI) associated with monoclonal antibody therapies (MTA) to improve cancer treatment outcomes.
- A comprehensive literature review was conducted, utilizing resources like case reports, FDA documents, and the LiverTox database to gather information on MTA-related hepatotoxicity.
- Although MTA-related liver issues are common, they are rarely life-threatening, and potential predictive methods like pharmacogenomics exist, but more research is needed; preventive measures focus on managing viral hepatitis and avoiding risky drug combinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!